News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Asthma Leader GlaxoSmithKline (GSK) Faces Competition From Roche (RHHBY), AstraZeneca PLC (AZN), Sanofi (France) (SAN.PA), And Teva Pharmaceutical Industries Limited (TEVA)


3/18/2014 7:29:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion. Britain's GlaxoSmithKline, the leader in asthma treatments since launching its Ventolin inhaler in 1969, is in the vanguard but faces competition from the likes of Roche, AstraZeneca, Sanofi and Teva. Despite treatment advances in recent decades, asthma is still not well controlled in up to 20 percent of patients on standard therapy, which consists of inhaled steroids and long-acting beta agonists that are designed to open the airways.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters

comments powered by Disqus
Reuters
   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES